Acute myeloid leukemia (AML) is the most common form of adult leukemia and has the lowest five-year overall survival rates of all blood cancers. Historically, the treatment of AML in China is managed with chemotherapy; however, the approvals of Celgene’s Vidaza (azacitidine) in 2017, Venclexta (venetoclax) and Xospata (gilteritinib) in 2021, and the expected approvals of several therapies available in Western markets during the forecast period will transform the AML treatment landscape in China. The entry of novel agents into the treatment paradigm will enable increasingly personalized treatment, but several areas of unmet need will remain. Most notably, significant commercial opportunity will exist for innovative agents to treat relapsed / refractory AML patients and those unfit for intensive chemotherapy induction. Additionally, with the ongoing reforms in China’s regulatory and access and reimbursement landscape, multinational companies are increasingly incentivized to enter the Chinese market.
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 75 hematologist-oncologists.
Diagnosed incidence of AML in urban versus rural China, clinically relevant and market-relevant drug-treatable populations.
10-year, annualized, drug-level sales and patient share of key AML therapies through 2031, based on primary and secondary market research to formulate bottom-up assumptions.
Phase III: 6 drugs. Phase I/II: 10+ drugs. Coverage of select early-phase products.